Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2024; 15(7): 1398-1403
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1398
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1398
MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease
Javier Donate-Correa, Ainhoa González-Luis, Jésica Díaz-Vera, Research Unit, University Hospital Nuestra Señora de Candelaria (UHNSC), Santa Cruz de Tenerife 38010, Spain
Juan Ramón Hernandez-Fernaud, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Santa Cruz de Tenerife 38000, Spain
Author contributions: Donate-Correa J, González-Luis A, Díaz-Vera J and Hernandez-Fernaud JR designed this editorial; González-Luis A, Díaz-Vera J and Hernandez-Fernaud JR contributed to the data collection and editing of the manuscript; Donate-Correa J wrote the paper; All the authors have read and approved the final version of the present manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Javier Donate-Correa, PhD, Research Scientist, Teacher, Research Unit, University Hospital Nuestra Señora de Candelaria (UHNSC), Carretera del Rosario S/N, Santa Cruz de Tenerife 38010, Spain. jdonatecorrea@gmail.com
Received: February 10, 2024
Revised: March 18, 2024
Accepted: April 22, 2024
Published online: July 15, 2024
Processing time: 148 Days and 15.3 Hours
Revised: March 18, 2024
Accepted: April 22, 2024
Published online: July 15, 2024
Processing time: 148 Days and 15.3 Hours
Core Tip
Core Tip: Targeting Toll-like receptors (TLRs) via microRNAs is a promising therapeutic approach for reducing inflammation and slowing the progression of diabetic kidney disease (DKD). Understanding how TLR4 expression and signaling are linked to microRNAs regulation, may pave the path for future targeted clinical interventions in DKD.